Fluoguide Q2 2024: Following the plan - Redeye

Redeye comments on Fluoguide’s Q2 2024 report, following its recent cSEK60m directed share issue that came at shareholder-friendly terms. We will closely watch FG001’s progression in clinical development and business development news in coming quarters. We do some housekeeping in our estimates and valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1036833/fluoguide-q2-2024-following-the-plan?utm_source=finwire&utm_medium=RSS